NATCO PHARMA LTDNATCO PHARMA LTDNATCO PHARMA LTD

NATCO PHARMA LTD

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪178.90 B‬INR
‪7.15 B‬INR
‪26.99 B‬INR
‪89.52 M‬
Beta (1Y)
0.58

About NATCO PHARMA LTD

CEO
Rajeev Nannapaneni
Headquarters
Hyderabad
Employees (FY)
‪4.49 K‬
Founded
1981
ISIN
INE987B01026
FIGI
BBG000F4LTG0
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NATCOPHARM is 998.00 INR — it has increased by 0.29% in the past 24 hours. Watch NATCO PHARMA LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange NATCO PHARMA LTD stocks are traded under the ticker NATCOPHARM.
NATCOPHARM stock has risen by 2.93% compared to the previous week, the month change is a 2.89% rise, over the last year NATCO PHARMA LTD has showed a 60.30% increase.
We've gathered analysts' opinions on NATCO PHARMA LTD future price: according to them, NATCOPHARM price has a max estimate of 1200.00 INR and a min estimate of 620.00 INR. Watch NATCOPHARM chart and read a more detailed NATCO PHARMA LTD stock forecast: see what analysts think of NATCO PHARMA LTD and suggest that you do with its stocks.
NATCOPHARM reached its all-time high on Jul 6, 2021 with the price of 1189.00 INR, and its all-time low was 1.70 INR and was reached on Jul 10, 2001. View more price dynamics on NATCOPHARM chart.
See other stocks reaching their highest and lowest prices.
NATCOPHARM stock is 0.29% volatile and has beta coefficient of 0.58. Track NATCO PHARMA LTD stock price on the chart and check out the list of the most volatile stocks — is NATCO PHARMA LTD there?
Today NATCO PHARMA LTD has the market capitalization of ‪178.90 B‬, it has increased by 2.52% over the last week.
Yes, you can track NATCO PHARMA LTD financials in yearly and quarterly reports right on TradingView.
NATCO PHARMA LTD is going to release the next earnings report on May 27, 2024. Keep track of upcoming events with our Earnings Calendar.
NATCOPHARM earnings for the last quarter are 11.90 INR per share, whereas the estimation was 7.04 INR resulting in a 69.15% surprise. The estimated earnings for the next quarter are 18.27 INR per share. See more details about NATCO PHARMA LTD earnings.
NATCO PHARMA LTD revenue for the last quarter amounts to ‪7.59 B‬ INR despite the estimated figure of ‪6.11 B‬ INR. In the next quarter revenue is expected to reach ‪9.87 B‬ INR.
NATCOPHARM net income for the last quarter is ‪2.13 B‬ INR, while the quarter before that showed ‪3.69 B‬ INR of net income which accounts for −42.36% change. Track more NATCO PHARMA LTD financial stats to get the full picture.
NATCO PHARMA LTD dividend yield was 0.98% in 2022, and payout ratio reached 14.04%. The year before the numbers were 0.59% and 48.27% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 18, 2024, the company has ‪4.49 K‬ employees. See our rating of the largest employees — is NATCO PHARMA LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NATCO PHARMA LTD EBITDA is ‪16.44 B‬ INR, and current EBITDA margin is 35.90%. See more stats in NATCO PHARMA LTD financial statements.
Like other stocks, NATCOPHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NATCO PHARMA LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NATCO PHARMA LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NATCO PHARMA LTD stock shows the buy signal. See more of NATCO PHARMA LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.